Novel TLR4 Adjuvant Elicits Protection Against Homologous and Heterologous Influenza A Infection

Overview

Journal Vaccine

Specialty Allergy & Immunology

Date 2021 Aug 7

PMID 34362603

Citations 11

Authors

Robert E Haupt

Erin M Harberts

Robert J Kitz

Shirin Strohmeier

Florian Krammer

Robert K Ernst

Matthew B Frieman

Affiliations

Soon will be listed here.

Abstract

Influenza A virus (IAV) is a leading cause of respiratory disease worldwide often resulting in hospitalization or death. In this study, TLR4 immunostimulatory molecules, Bacterial Enzymatic Combinatorial Chemistry (BECC) 438 and BECC470 were found to be superior IAV vaccine adjuvants when compared to the classic adjuvant alhydrogel (alum) and Phosphorylated Hexa-Acyl Disaccharide (PHAD), a synthetic TLR4 agonist. BECC molecules allow for antigen sparing of a recombinant HA (rHA) protein, elicit a more balanced IgG1/IgG2a response, and were protective in a prime only dosing schedule. Importantly, BECC molecules afford protection from a heterologous IAV strain demonstrating that a cross-protective influenza vaccine is possible when the antigen is effectively adjuvanted.

Citing Articles

Immune profile diversity is achieved with synthetic TLR4 agonists combined with the RG1-VLP vaccine in mice.

Matthews R, Khan N, Beckman B, Sharma S, Dietz Z, Picking W Vaccine. 2024; 44:126577.

PMID: 39632208 PMC: 11655249. DOI: 10.1016/j.vaccine.2024.126577.

Influenza virus strains expressing SARS-CoV-2 receptor binding domain protein confer immunity in K18-hACE2 mice.

Rader N, Lee K, Loes A, Miller-Stump O, Cooper M, Wong T Vaccine X. 2024; 20:100543.

PMID: 39221180 PMC: 11364132. DOI: 10.1016/j.jvacx.2024.100543.

BECC-engineered live-attenuated vaccine candidates display reduced endotoxicity with robust immunogenicity in mice.

Sherman M, Michalski J, Das S, Yang H, Chandrasekaran L, OMeara T Res Sq. 2024; .

PMID: 38946947 PMC: 11213197. DOI: 10.21203/rs.3.rs-4448907/v1.

Vaccination with a Protective Ipa Protein-Containing Nanoemulsion Differentially Alters the Transcriptomic Profiles of Young and Elderly Mice following Infection.

Lu T, Raju M, Howlader D, Dietz Z, Whittier S, Varisco D Vaccines (Basel). 2024; 12(6).

PMID: 38932347 PMC: 11209624. DOI: 10.3390/vaccines12060618.

BECC438b TLR4 agonist supports unique immune response profiles from nasal and muscular DTaP pertussis vaccines in murine challenge models.

DeJong M, Wolf M, Bitzer G, Hall J, Fitzgerald N, Pyles G Infect Immun. 2024; 92(3):e0022323.

PMID: 38323817 PMC: 10929442. DOI: 10.1128/iai.00223-23.

References

Mothes N, Heinzkill M, Drachenberg K, Sperr W, Krauth M, Majlesi Y . Allergen-specific immunotherapy with a monophosphoryl lipid A-adjuvanted vaccine: reduced seasonally boosted immunoglobulin E production and inhibition of basophil histamine release by therapy-induced blocking antibodies. Clin Exp Allergy. 2003; 33(9):1198-208. DOI: 10.1046/j.1365-2222.2003.01699.x. View

Goff P, Hayashi T, Martinez-Gil L, Corr M, Crain B, Yao S . Synthetic Toll-like receptor 4 (TLR4) and TLR7 ligands as influenza virus vaccine adjuvants induce rapid, sustained, and broadly protective responses. J Virol. 2015; 89(6):3221-35. PMC: 4337541. DOI: 10.1128/JVI.03337-14. View

Gregg K, Harberts E, Gardner F, Pelletier M, Cayatte C, Yu L . Rationally Designed TLR4 Ligands for Vaccine Adjuvant Discovery. mBio. 2017; 8(3). PMC: 5424205. DOI: 10.1128/mBio.00492-17. View

Taubenberger J, Morens D . 1918 Influenza: the mother of all pandemics. Emerg Infect Dis. 2006; 12(1):15-22. PMC: 3291398. DOI: 10.3201/eid1201.050979. View

Treanor J . Influenza vaccine--outmaneuvering antigenic shift and drift. N Engl J Med. 2004; 350(3):218-20. DOI: 10.1056/NEJMp038238. View

Ko E, Kang S . Immunology and efficacy of MF59-adjuvanted vaccines. Hum Vaccin Immunother. 2018; 14(12):3041-3045. PMC: 6343625. DOI: 10.1080/21645515.2018.1495301. View

Hem S, White J . Structure and properties of aluminum-containing adjuvants. Pharm Biotechnol. 1995; 6:249-76. DOI: 10.1007/978-1-4615-1823-5_9. View

Gregg K, Harberts E, Gardner F, Pelletier M, Cayatte C, Yu L . A lipid A-based TLR4 mimetic effectively adjuvants a Yersinia pestis rF-V1 subunit vaccine in a murine challenge model. Vaccine. 2018; 36(28):4023-4031. PMC: 6057149. DOI: 10.1016/j.vaccine.2018.05.101. View

Hernandez A, Luan L, Stothers C, Patil N, Fults J, Fensterheim B . Phosphorylated Hexa-Acyl Disaccharides Augment Host Resistance Against Common Nosocomial Pathogens. Crit Care Med. 2019; 47(11):e930-e938. PMC: 6791756. DOI: 10.1097/CCM.0000000000003967. View

10.

Xu X, Blanton L, Abd Elal A, Alabi N, Barnes J, Biggerstaff M . Update: Influenza Activity in the United States During the 2018-19 Season and Composition of the 2019-20 Influenza Vaccine. MMWR Morb Mortal Wkly Rep. 2019; 68(24):544-551. PMC: 6586370. DOI: 10.15585/mmwr.mm6824a3. View

11.

Martinon S, Cisneros A, Villicana S, Hernandez-Miramontes R, Mixcoha E, Calderon-Vargas P . Chemical and Immunological Characteristics of Aluminum-Based, Oil-Water Emulsion, and Bacterial-Origin Adjuvants. J Immunol Res. 2019; 2019:3974127. PMC: 6530223. DOI: 10.1155/2019/3974127. View

12.

Molinari N, Ortega-Sanchez I, Messonnier M, Thompson W, Wortley P, Weintraub E . The annual impact of seasonal influenza in the US: measuring disease burden and costs. Vaccine. 2007; 25(27):5086-96. DOI: 10.1016/j.vaccine.2007.03.046. View

13.

Nelson M, Holmes E . The evolution of epidemic influenza. Nat Rev Genet. 2007; 8(3):196-205. DOI: 10.1038/nrg2053. View

14.

Chandler C, Harberts E, Pelletier M, Thaipisuttikul I, Jones J, Hajjar A . Early evolutionary loss of the lipid A modifying enzyme PagP resulting in innate immune evasion in . Proc Natl Acad Sci U S A. 2020; 117(37):22984-22991. PMC: 7502761. DOI: 10.1073/pnas.1917504117. View

15.

Takayama K, Qureshi N, Ribi E, Cantrell J . Separation and characterization of toxic and nontoxic forms of lipid A. Rev Infect Dis. 1984; 6(4):439-43. DOI: 10.1093/clinids/6.4.439. View

16.

Clark A, DeDiego M, Anderson C, Wang J, Yang H, Nogales A . Antigenicity of the 2015-2016 seasonal H1N1 human influenza virus HA and NA proteins. PLoS One. 2017; 12(11):e0188267. PMC: 5690631. DOI: 10.1371/journal.pone.0188267. View

17.

Ghimire T . The mechanisms of action of vaccines containing aluminum adjuvants: an in vitro vs in vivo paradigm. Springerplus. 2015; 4:181. PMC: 4406982. DOI: 10.1186/s40064-015-0972-0. View

18.

Qureshi N, Takayama K, Ribi E . Purification and structural determination of nontoxic lipid A obtained from the lipopolysaccharide of Salmonella typhimurium. J Biol Chem. 1982; 257(19):11808-15. View

19.

Suarez D, Senne D, Banks J, Brown I, Essen S, Lee C . Recombination resulting in virulence shift in avian influenza outbreak, Chile. Emerg Infect Dis. 2004; 10(4):693-9. PMC: 3323103. DOI: 10.3201/eid1004.030396. View

20.

Gao J, Guo Z . Progress in the synthesis and biological evaluation of lipid A and its derivatives. Med Res Rev. 2017; 38(2):556-601. PMC: 5732894. DOI: 10.1002/med.21447. View